Tag Archive for: Evotec

Nathaniel Martin_university Leiden

A Dutch-German resarch team together with Evotec SE have presented a new class of vancomycin derivatives with good safety profile that kill multi-resistant, Gram-positive bugs.

Evotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.

Misfolded protein accumulation and evidence of ISR activationis present in multiple neurological conditions. © BMS and Hetz et al, Nat Rev – Neur 2017

Evotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).

Evotec headquarters in Hamburg. © Evotec SE

Drug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.

@ BMS

German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.

 

Lung cancer cells. © Evotec SE

Evotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.

Picture: Aurobac

Aurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance (AMR).